Latest Breaking News On - Novarti lucentis - Page 1 : comparemela.com
Regeneron hit with DOJ complaint that it hid hundreds of millions in Eylea credit card processing fees from Medicare
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
NHS wins legal fight with pharma over off-label Avastin
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Fierce Pharma Asia—Enhertu s big win; Biogen-Samsung s Lucentis biosimilar; Clover s COVID vaccine data
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Feb 2, 2021 10:50am
Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ PD-1 inhibitor toripalimab. (Kritchanut/iStock/Getty Images Plus/Getty Images)
On the heels of Novartis licensing BeiGene’s tislelizumab, another China-made PD-1 inhibitor has found itself a new U.S. collaborator in a company that’s just pivoting to immuno-oncology.
Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ anti-PD-1 antibody toripalimab, which was first approved in China for previously treated melanoma in late 2018. Up to $380 million in milestone payments and a 20% royalty on net sales are also up for grabs.